Philips shares rise 10% as health tech company notes lower U.S. tariff effects

The European market appears to be shedding the concerns surrounding the EU-US trade agreement, as revenue reports are coming in better than anticipated. The Stoxx 600 index has risen by 0.57%, while both the CAC40 in France and Germany’s index are expected to increase by roughly 1%.

Phillips has seen its profits rise by 10% after the consumer health technology firm announced it expects an improvement in tariffs. “Overall, we have momentum, and we aim to carry this forward into the second half while clarifying the tariff situation,” the company commented.

Additionally, essilorluxottica has proven to be a strong performer with a revenue growth of 7.3% in both halves of the year, largely driven by rising demands for smart glasses. Sales of Ray-Ban Meta Glasses tripled in the first six months.

AstraZeneca’s stock increased by 1.75% following a robust second-quarter revenue report, which surpassed expectations.

In contrast, Stellantis’s stock fell by 2.1%, despite the car manufacturer expressing hope for a gradual financial recovery.

Phillips surged nearly 14% at market opening, following the consumer healthcare group’s increased expectations for its full-year margins. The company anticipates a range of €15-200 million, improving from prior estimates of €250-300 million.

Sales for the second quarter reached €4.3 billion, aligning with analyst expectations.

– Matt Ward Perkins, Jenni Reed

Barclays, the British bank, surpassed profit expectations and announced a £1 billion ($1.3 billion) share buyback, bolstered by increased investment banking revenues amid market volatility.

The estimated pre-tax profit stands at £2.5 billion ($3.34 billion) for the second quarter, exceeding the average forecast of £2.23 billion from LSEG. Group revenues met analysts’ expectations, totaling £7.2 billion.

AstraZeneca reported better-than-expected revenues for the second quarter, attributed to strong demand in cancer and biopharmaceutical sectors. The firm generated $14.46 billion in revenue for the three months ending June 30, surpassing the $14.07 billion predicted by analysts.

Core operating income reached $4.488 billion, slightly above the anticipated $4.48 billion. The company remains optimistic, maintaining its annual revenue forecasts and aims for a 9% increase despite geopolitical tensions. AstraZeneca plans to invest $50 billion by 2030 to boost its US manufacturing and research capabilities.

Good morning from London.

According to IG data, European stock markets appear set for a positive opening today, with major indexes gaining around 0.2%. However, the initial optimism regarding the EU-US trade framework waned by the end of the previous session, leading the STOXX 600 index to a 0.23% decline. Investors continue to scrutinize today’s outlook, amid uncertainties surrounding key products like medicines and spirits.

Standard Chartered’s analyst, Steve England, noted that while global trade appears negative, it seems manageable for US trading partners. Attention is also on upcoming reports from Barclays, L’Oreal, AstraZeneca, and others.